Organovo Holdings, Inc.

Organovo Holdings, Inc. is a San Diego-based company pioneering the use of 3D bioprinting technology to create functional human tissues for drug discovery and therapeutic applications. Their primary focus is on the development of novel medicines based on their 3D human tissue models, particularly for the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Their lead therapeutic molecule, FXR314, has demonstrated promising results in preclinical testing and is currently undergoing Phase 2 clinical trials for ulcerative colitis. Organovo is also expanding their portfolio to include therapeutic tissues for liver diseases and oncology.

Organovo’s 3D bioprinting technology allows them to create human tissue models that more accurately mimic the complexities of human biology and disease, leading to more reliable and efficient drug discovery processes. This technology has the potential to fundamentally alter the drug development landscape by reducing the cost and time associated with traditional drug development methods. Organovo is committed to advancing their technology and expanding their product offerings, aiming to become a leading player in the regenerative medicine and drug discovery sectors.

Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology. They create functional, three-dimensional human tissues for use in medical research and therapeutic applications, with the goal of accelerating the drug discovery process and enabling treatments to be developed faster and at lower cost. Organovo's 3D human tissues have the potential to revolutionize preclinical drug testing, disease modeling, and even direct surgical applications.

Organovo Holdings, Inc. fosters a culture of innovation and collaboration, focused on advancing regenerative medicine therapies to address a range of serious liver diseases. With decades of leadership experience in the life science industry, the team promotes a shared passion for developing groundbreaking 3D human tissue models that can revolutionize drug discovery and treatment. This commitment to scientific excellence, combined with a forward-thinking approach, creates an environment where employees can contribute their expertise and work together to make a tangible impact on human health.